Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A novel Bayesian decision procedure for early-phase dose-finding studies.

S Patterson1, S Francis, M Ireson

  • 1Clinical Pharmacology Statistics, Biostatistics and Data Sciences, SmithKline Beecham Pharmaceuticals, Philadelphia, Pennsylvania 19101-7929, USA.

Journal of Biopharmaceutical Statistics
|November 27, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

VCING Scoring and White Matter Arteriolosclerosis Show Relationships to Dementia Status and White Matter Damage in an Unselected Ageing Brain Cohort.

Neuropathology and applied neurobiology·2026
Same author

Supporting Canadian families of children with disabilities: unmet needs and service gaps.

Frontiers in public health·2026
Same author

Rurality, Deprivation and Ethnicity in New Zealand: Population Distributions and Intersecting Impacts on Mortality.

The Australian journal of rural health·2026
Same author

Cryoablation: A Minimally Invasive Alternative for Early-Stage Breast Cancer: 6-Year Outcomes of the FROST Clinical Trial.

Annals of surgical oncology·2026
Same author

Early mobilisation practices in Windhoek intensive care units: A retrospective review of patient profiles and physiotherapy practice.

The Southern African journal of critical care : the official journal of the Critical Care Society·2025
Same author

Stressors faced by forcibly displaced Ukrainians in England within 6 months of arrival: A qualitative study.

Social science & medicine (1982)·2025
Same journal

Correction.

Journal of biopharmaceutical statistics·2026
Same journal

Leveraging external controls in clinical trials: estimands, estimation, assumptions.

Journal of biopharmaceutical statistics·2026
Same journal

Special issue of nonclinical statistics in regulatory applications guest editors' notes.

Journal of biopharmaceutical statistics·2026
Same journal

Comparison of flexible parametric modeling and nonparametric methods to estimate restricted mean survival time: A simulation study.

Journal of biopharmaceutical statistics·2026
Same journal

Simulated treatment comparisons with jackknife pseudo values for estimating population-adjusted marginal treatment effects.

Journal of biopharmaceutical statistics·2026
Same journal

Sample sizes for randomized controlled trials utilizing Bayesian response adaptive randomization for continuous outcomes.

Journal of biopharmaceutical statistics·2026
See all related articles

This study introduces new software for Phase I clinical trials. It uses Bayesian analysis and decision theory to find safe drug doses faster in healthy volunteers.

Area of Science:

  • Pharmacology
  • Clinical Pharmacology
  • Biostatistics

Background:

  • Phase I clinical trials in healthy volunteers are crucial for determining safe drug dosage ranges.
  • Traditional methods for dose determination can be time-consuming and may not fully optimize data utilization.

Purpose of the Study:

  • To describe novel software for Phase I clinical trial dose selection.
  • To illustrate a methodology integrating pharmacokinetic and pharmacodynamic data analysis.

Main Methods:

  • Utilizing mixed-effects modeling for dose-response relationship analysis.
  • Employing Bayesian analysis with pseudodata to estimate model parameters.
  • Applying decision theory with real-time data capture for adaptive dose selection.

Related Experiment Videos

Main Results:

  • The described methodology and software enable efficient identification of maximum safe doses.
  • The approach facilitates more informative study responses, potentially accelerating drug development.

Conclusions:

  • The developed software and integrated methodology offer a robust approach to optimizing dose selection in early-phase drug development.
  • This innovative method enhances the safety and efficiency of Phase I clinical studies.